Prostate cancer other imaging findings: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} {{AE}} {{sali}} | {{CMG}} {{AE}} {{sali}} | ||
{{Prostate cancer}} | {{Prostate cancer}} | ||
| Line 6: | Line 7: | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
:* Test results suggest spread to the bone, such as increased [[alkaline phosphatase]] or [[calcium]] level | *A [[Radionuclide]] uses bone-seeking radioactive materials ([[radiopharmaceuticals]]) and a computer to create a picture of the [[bones]].<ref>Diagnosing prostate cancer.2015 Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/prostate/diagnosis/?region=ab#Bone_scan </ref> | ||
:* A man has unexplained [[bone pain]] | *It is used to see if the prostate cancer has spread to the [[bones]] (the most common place where prostate cancer spreads). | ||
*It may be done if: | |||
:*Test results suggest spread to the bone, such as increased [[alkaline phosphatase]] or [[calcium]] level | |||
:*A man has unexplained [[bone pain]] | |||
==PET SCAN== | ==PET SCAN== | ||
*PET scan has emerged as a promising staging modality for both primary and recurrent prostate cancer. | *[[PET scan]] has emerged as a promising staging modality for both primary and recurrent prostate cancer. | ||
*Newer tracers have increased detection accuracies for small, incipient metastatic foci. The clinical implications of these occult PET/CT detected disease foci require organized evaluation. | *Newer tracers have increased detection accuracies for small, incipient metastatic foci. The clinical implications of these occult PET/CT detected disease foci require organized evaluation. | ||
*A classical positron emission tomography (PET scan) 18-F-fluorodeoxyglucose (FDG) is of limited utility in the management of prostate cancer, as the uptake of FDG in prostate cancer is highly variable. | *A classical positron emission tomography ([[PET scan]]) 18-F-fluorodeoxyglucose (FDG) is of limited utility in the management of prostate cancer, as the uptake of [[FDG]] in prostate cancer is highly variable. | ||
*Early studies suggest that 18-fluorine-labeled choline, 18-F sodium fluoride, fluciclovine F-18, and 11-carbon-labeled acetate may be better tracers for use in recurrent prostate cancer. Currently, the use of these tracers is considered investigational.<ref name="pmid29230009">{{cite journal |vauthors=Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF |title=The use of PET/CT in prostate cancer |journal=Prostate Cancer Prostatic Dis. |volume=21 |issue=1 |pages=4–21 |date=April 2018 |pmid=29230009 |doi=10.1038/s41391-017-0007-8 |url=}}</ref> | *Early studies suggest that 18-fluorine-labeled choline, 18-F sodium fluoride, fluciclovine F-18, and 11-carbon-labeled acetate may be better tracers for use in recurrent prostate cancer. Currently, the use of these tracers is considered investigational.<ref name="pmid29230009">{{cite journal |vauthors=Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF |title=The use of PET/CT in prostate cancer |journal=Prostate Cancer Prostatic Dis. |volume=21 |issue=1 |pages=4–21 |date=April 2018 |pmid=29230009 |doi=10.1038/s41391-017-0007-8 |url=}}</ref> | ||
Revision as of 14:41, 14 January 2021
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Syed Musadiq Ali M.B.B.S.[2]
|
Prostate cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prostate cancer other imaging findings On the Web |
|
American Roentgen Ray Society Images of Prostate cancer other imaging findings |
|
Risk calculators and risk factors for Prostate cancer other imaging findings |
Overview
Radionuclide may be helpful in the diagnosis of bone metastasis of prostate cancer.
Other Imaging Findings
- A Radionuclide uses bone-seeking radioactive materials (radiopharmaceuticals) and a computer to create a picture of the bones.[1]
- It is used to see if the prostate cancer has spread to the bones (the most common place where prostate cancer spreads).
- It may be done if:
- Test results suggest spread to the bone, such as increased alkaline phosphatase or calcium level
- A man has unexplained bone pain
PET SCAN
- PET scan has emerged as a promising staging modality for both primary and recurrent prostate cancer.
- Newer tracers have increased detection accuracies for small, incipient metastatic foci. The clinical implications of these occult PET/CT detected disease foci require organized evaluation.
- A classical positron emission tomography (PET scan) 18-F-fluorodeoxyglucose (FDG) is of limited utility in the management of prostate cancer, as the uptake of FDG in prostate cancer is highly variable.
- Early studies suggest that 18-fluorine-labeled choline, 18-F sodium fluoride, fluciclovine F-18, and 11-carbon-labeled acetate may be better tracers for use in recurrent prostate cancer. Currently, the use of these tracers is considered investigational.[2]
References
- ↑ Diagnosing prostate cancer.2015 Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/prostate/diagnosis/?region=ab#Bone_scan
- ↑ Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF (April 2018). "The use of PET/CT in prostate cancer". Prostate Cancer Prostatic Dis. 21 (1): 4–21. doi:10.1038/s41391-017-0007-8. PMID 29230009.